Edgewise Therapeutics, Inc.

EWTX · Healthcare

$42.25

Market cap: 4.59B USDDividend yield: —
AdvanceIs it a good moment to buy Edgewise Therapeutics, Inc.? Ask Copenvest AIGet an Advance AI take on timing, risk, and what tracked investors are doing.Ask Copenvest AI

Loading chart…

News

Latest headlines for this stock

Zacks Investment ResearchSep 4, 2026, 7:36 PM

Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?

Bristol Myers Squibb's Camzyos demonstrated durable reductions in LVOT obstruction over five years with 97.4% of patients achieving target gradients. Sales surged 74% year-over-year to $729 million in H1 2026. The company seeks FDA approval for adolescents with a decision expected by September 30, 2026. However, competition is intensifying with Cytokinetics' Myqorzo approved in December 2025 and Edgewise Therapeutics advancing EDG-7500 in clinical trials.

Zacks Investment ResearchSep 2, 2026, 6:30 PM

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Cytokinetics announced additional positive results from ACACIA-HCM and MAPLE-HCM studies showing aficamten improved cardiac structure and diastolic function in non-obstructive HCM patients, and outperformed metoprolol in obstructive HCM. The company plans to file for nHCM approval in Q4 2026, potentially expanding the drug's addressable market. Myqorzo received FDA approval in December 2025 for obstructive HCM treatment.